HOME >> BIOLOGY >> NEWS
Zengen, Inc. receives patent application approval for proprietary peptide technology

WOODLAND HILLS, Calif. (October 2, 2003) - Zengen, Inc. announced today that the United States Patent Office has approved a patent application for "A Lys-Pro-Val Dimer, Formulations and Applications," which covers novel peptide CZEN 002. This marks the first patent application approval for CZEN 002, with issuance of the patent expected by the end of the year. In addition, Zengen holds multiple patents and patents-pending worldwide on its peptide technologies.

"This development provides further validation of the efficacy of CZEN 002," said R. Steven Davidson, Ph.D., President and CEO of Zengen. "The approved patent application claims are directed to the novel peptide, which has the ability to control infection and/or inflammation associated with, among other disease states, urogenital conditions, including vaginitis."

Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Company's proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. Zengen's peptides have broad applications as anti-inflammatory and anti-infective prescription pharmaceuticals and are based on the larger melanocortin peptide, alpha-Melanocyte-Stimulating Hormone (a-MSH).

About CZEN 002

A synthetic octapeptide, CZEN 002 was developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). There is abundant evidence of the anti-inflammatory and anti-infective activity of CZEN 002 from both in vivo and in vitro research.

Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth and subsequent interference with cell metabolism, all of which give rise to a broad range of life-threatening diseases and disorders. In preclinical and clinical studies, CZEN 002 has been shown to directly kill pathologi
'"/>

Contact: Kumiko Hakushi
hakushik@ruderfinn.com
310-479-9929
Zengen
2-Oct-2003


Page: 1 2

Related biology news :

1. Zengen, Inc. announces novel approach to reduce organ rejection
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
5. Research on carbohydrate metabolism receives historical recognition
6. K-States National Agricultural Biosecurity Center receives $1.3 Million from Department of Defense
7. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
8. NJIT professor receives Presidential Award for breakthrough research with adult stem cells
9. University of Pittsburgh receives $10 million grant for head and neck cancer
10. LSU Vet School receives $9.9 million for infectious disease research
11. UCSB professor and director receives two national awards

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... (PRWEB) , ... June 21, 2017 , ... ... regional office in North Carolina, and engages Timothy Reinhardt to manage the new ... quality leadership at Pfizer Inc, with his most recent role as the Director ...
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation Fertility supports the ... disease, bringing new hope for prospective parents who are challenged with costs of ... the World Health Organization’s designation in hopes of changing the way health insurers, ...
(Date:6/22/2017)... ... 2017 , ... The first human cell line HeLa, established in 1951, has ... cross-contamination of human cell lines with HeLa cells were published. Until recently, cross-contamination and ... and is associated with dramatic consequences for research. , In this educational webinar, ...
(Date:6/20/2017)... ... 20, 2017 , ... CTNext , Connecticut’s go-to resource ... a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of the master ... representatives from 35 higher education institutions across the state over the past six ...
Breaking Biology Technology:
Cached News: